Skip to search formSkip to main contentSkip to account menu

NUC-1031

Known as: Gemcitabine-Phosphoramidate Hydrochloride NUC-1031, Gemictabine ProTide 
A pyrimidine analogue and a proprietary prodrug based on an aryloxy phosphoramidate derivative of gemcitabine with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (1)

Cytidine Monophosphate
DNA Synthesis InhibitionNCIt Antineoplastic Agent TerminologyNucleotide BiosynthesisPositive Regulation of Apoptosis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).
TPS602Background: Biliary tract cancer (BTC) carries a poor prognosis and has no approved treatments. Although gemcitabine… 
2020
2020
NuTide: 302—A phase Ib study of the ProTide NUC-3373 in combination with standard therapies in advanced colorectal cancer.
TPS274Background: Although 5-FU-based regimens such as FOLFOX and FOLFIRI remain the cornerstone of treatment for patients (pts… 
2019
2019
NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.
TPS4156 Background: Cisplatin and gemcitabine (CisGem) is the global standard of care for 1st-line treatment of patients (pts… 
2018
2018
ABC-08: A phase Ib, multi-centre, open-label study of a first-in-class nucleotide analogue NUC-1031 in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers
TPS544Background: The UK ABC-02 study established cisplatin and gemcitabine as the reference regimen for first-line treatment of… 
2018
2018
Abstract 1855: NUC-1031 overcomes resistance associated with gemcitabine in cancer patients
NUC-1031 (NuCana plc) is a phosphoramidate transformation of gemcitabine and the first anti-cancer compound based on ProTide… 
2018
2018
PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.
TPS5612Background: Patients with platinum-resistant ovarian cancer, following ≥3 lines of chemotherapy have limited treatment… 
2013
2013
ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors [Abstract]
Background: NUC-1031 is a novel nucleotide (ProTide) that evades all three key cellular resistance mechanisms associated with… 
2011
2011
A phosphoramidate ProTide (NUC-1031) and acquired and intrinsic resistance to gemcitabine.
e13540 Background: Resistance to gemcitabine is a major problem in the treatment of cancer. The key resistance mechanisms… 
Highly Cited
2007
Highly Cited
2007
First example of phosphoramidate approach applied to a 4'-substituted purine nucleoside (4'-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus.
We report on the synthesis of the anti hepatitis C virus (HCV) agent 4'-azidoadenosine (1) and the application of the… 
2004
2004
Chimie et morphologie submicroscopique des parois cellulaires de l'AscomycèteChaetomium globosum
SummaryThe chemical composition and submicroscopic morphology of the hyphal cell walls of the AscomyceteChaetomium globosum… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)